A case of secondary adrenocortical insufficiency due to isolated adrenocorticotropic hormone deficiency with empty sella syndrome after pembrolizumab treatment in a patient with metastatic renal pelvic cancer

Pembrolizumab, an anti-programmed death-1 specific monoclonal antibody is a second-line treatment for metastatic urothelial carcinoma. Physicians should be aware of adverse immune-related events associated with the use of immune checkpoint inhibitors, particularly adrenocortical insufficiency, which...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagai, Takashi, Mogami, Tohru, Takeda, Tomoki, Tomiyama, Nami, Yasui, Takahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273353/
https://www.ncbi.nlm.nih.gov/pubmed/34285878
http://dx.doi.org/10.1016/j.eucr.2021.101766

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273353/
https://www.ncbi.nlm.nih.gov/pubmed/34285878
http://dx.doi.org/10.1016/j.eucr.2021.101766

Ejemplares similares